The impact of Covid-19 ventilator shortage on medical device regulation
International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia | European Respiratory Society
Microbiology of Ventilator-Associated Pneumonia | IntechOpen
JCM | Free Full-Text | Epidemiology, Treatment, and Prevention of Nosocomial Bacterial Pneumonia | HTML
Ventilator-associated pneumonia: A review of the clinically relevant challenges in diagnosis and prevention | BJMP.org
How regulatory changes for medical devices sector are impacting manufacturers | The Financial Express
Treatment algorithm for ventilator-associated pneumonia (VAP). CDC,... | Download Scientific Diagram
The global prevalence of multidrug-resistance among Acinetobacter baumannii causing hospital-acquired and ventilator-associated pneumonia and its associated mortality: A systematic review and meta-analysis - Journal of Infection
Review of Hospital-Acquired, Ventilator-Associated, and Health Care–Associated Pneumonia in Immunocompetent Adults
Bacteriological profile of ventilator-associated pneumonia in a tertiary care hospital Patro S, Sarangi G, Das P, Mahapatra A, Mohapatra D, Paty BP, Chayani N - Indian J Pathol Microbiol
Early intervention with empirical antibacterials is essential in the treatment of ventilator-associated pneumonia | SpringerLink
Ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: understanding nebulization of aminoglycosides and colistin | SpringerLink
Ventilator-Associated Pneumonia | SpringerLink
Ventilator-associated Pneumonia Incidence in COVID-19 Patients | RT
Ventilator-associated pneumonia in patients with cancer: Impact of multidrug resistant bacteria
OES Medical to launch new ventilator at Arab Health - Med-Tech Innovation
Determinants and impact of multidrug antibiotic resistance in pathogens causing ventilator-associated-pneumonia | Critical Care | Full Text
Ceftolozane/tazobactam versus colistin in the treatment of ventilator-associated pneumonia due to extensively drug-resistant Pseudomonas aeruginosa | Scientific Reports
Ventilator-associated pneumonia in the era of COVID-19 pandemic: How common and what is the impact? | Critical Care | Full Text
Respective impact of implementation of prevention strategies, colonization with multiresistant bacteria and antimicrobial use on the risk of early- and late-onset VAP: An analysis of the OUTCOMEREA network | PLOS ONE
Respiratory research networks in Europe and beyond: aims, achievements and aspirations for the 21st century | European Respiratory Society
ISO MDD to MDR Transition and Similarities Between ISO 13485:2016 and MDR | SGS
Management of Ventilator-Associated Pneumonia - Clinics in Chest Medicine
JKMS :: Journal of Korean Medical Science
Downloads and Resources
13 Ways to Combat Multidrug Resistant Organisms and Ventilator-associated Pneumonia | RT
Levofloxacin in the treatment of ventilator-associated pneumonia - Clinical Microbiology and Infection
